AI Applications Summit: Healthcare, Pharma, Biotech

Thriving in the New Data-Driven Healthcare Market

  • What are the goals of this data-driven revolution and how far are we from starting to achieve them?
  • Will a completely new business paradigm emerge for next-generation health systems to optimize operations and patient care?
  • Is there room for disruptive entrepreneurs alongside existing companies to succeed in data-driven drug discovery and development?
  • Roll up your sleeves and get ready to discuss what is working and what is getting in the way of flourishing in the world of MoneyBall Medicine

Harry Glorikian
General Partner, New Ventures Funds;
Author, MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.

He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Harry holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.